Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers.

Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of administration. The UK was an early adopter of SC daratumumab and, as such, this report provides consensus recommendations from a group of UK MM experts, with the aim of facilitating the transition from IV to SC daratumumab for other European healthcare providers. The switch from IV to SC daratumumab has been beneficial to patients and healthcare providers, as it simplifies treatment, reduces pressure on hospitals and can improve patients' quality of life.

Informations de copyright

Copyright © 2023 Cook, Ashcroft, Fernandez, Henshaw, Khalaf, Pratt, Tailor and Rabin.

Déclaration de conflit d'intérêts

GC: Consultancy for Amgen, Bristol Myers Squibb, IQVIA, Janssen, Karyopharm, Oncopeptides, Roche, Sanofi, and Takeda; research funding from Bristol Myers Squibb, IQVIA and Takeda. JA: Speaker and consultancy for Amgen, Bristol Myers Squibb Celgene, Janssen and Takeda. MF: Employee of Janssen. SH: Funding from Amgen, Bristol Myers Squibb Celgene, Janssen, Sanofi and Takeda. ZK: Employee of GSK, former employee of Janssen. AT: Funding from Janssen. GP: Medical advisory board of Binding Site Ltd. Speaker and consultancy for Beigene, Bristol Myers Squibb Celgene, Gilead, Janssen-Cilag, Sanofi, Takeda. NR: Speaker and consultancy for Bristol Myers Squibb Celgene, GlaxoSmithKline, Janssen, Karyopharm, Sanofi and Takeda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.